These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26104035)

  • 1. Evidence supporting the need for considering the effects of smoking on drug disposition and effectiveness in medication practices: a systematic narrative review.
    Sohn HS; Kim H; Song IS; Lim E; Kwon M; Ha JH; Kwon JW
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):621-34. PubMed ID: 26104035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tobacco smoking and drug interactions].
    Molden E; Spigset O
    Tidsskr Nor Laegeforen; 2009 Mar; 129(7):632-3. PubMed ID: 19337332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Recent Advances in Developmental Drug Disposition.
    Collier AC
    Drug Metab Lett; 2015; 9(2):64. PubMed ID: 26517862
    [No Abstract]   [Full Text] [Related]  

  • 5. Cigarette smoking and clinically significant drug interactions.
    Schein JR
    Ann Pharmacother; 1995 Nov; 29(11):1139-48. PubMed ID: 8573960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics.
    Miyagi SJ; Long-Boyle JR
    Drug Metab Lett; 2015; 9(2):80-7. PubMed ID: 26031462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [FOOD - DRUG INTERACTIONS: TYPES AND MECHANISMS.].
    Lemina EY; Churyukanov VV
    Eksp Klin Farmakol; 2016; 79(11):41-44. PubMed ID: 29791108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling.
    Li H; Shi Q
    Clin Pharmacokinet; 2015 May; 54(5):493-501. PubMed ID: 25701380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microdosing Studies in Children: A US Regulatory Perspective.
    Roth-Cline M; Nelson RM
    Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effects of Obesity on Drug Metabolism in Children.
    Oeser SG; Rougee LR; Collier AC
    Drug Metab Lett; 2015; 9(2):88-98. PubMed ID: 26411468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug interactions. Mechanisms and clinical relevance].
    Klotz U; Beil W; Gleiter C; Drewelow B; Garbe E; Gillessen A; Mutschler E
    Internist (Berl); 2003 Nov; 44(11):1444-9. PubMed ID: 14689079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting the proper pediatric dose: It is more than size that matters.
    Kearns GL
    Clin Pharmacol Ther; 2015 Sep; 98(3):238-40. PubMed ID: 26073060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Nishinarita N; Igawa S; Kasajima M; Kusuhara S; Harada S; Okuma Y; Sugita K; Ozawa T; Fukui T; Mitsufuji H; Yokoba M; Katagiri M; Kubota M; Sasaki J; Naoki K
    Oncology; 2018; 95(2):109-115. PubMed ID: 29698957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
    J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
    Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease.
    Weir MR; Fink JC
    Curr Opin Nephrol Hypertens; 2014 May; 23(3):306-13. PubMed ID: 24670404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel.
    Yousef AM; Arafat T; Bulatova NR; Al-Zumyli R
    J Clin Pharm Ther; 2008 Aug; 33(4):439-49. PubMed ID: 18613862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
    Garrett M; Taylor T; Mould DR; Amantea MA; Chen Y; Ingrosso A; Pithavala YK
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1131-1141. PubMed ID: 27783139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
    Velenosi TJ; Urquhart BL
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.